Evaluation of Effect of Composite AYUSH Treatment as Prophylaxis of COVID 19
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Episodes and severity of symptoms of respiratory tract infection (cold, sore throat, dry cough, breathlessness) in subjects who may get direct or indirect exposure to COVID 19 during lockdown in March and April 2020
研究概览
简要总结
The COVID 19 outbreak has been declared as pandemic by the world health organisation. In view of lack of precise treatment or vaccine, the incidence and mortality due to the infection remain high and are very high. Ayurveda explains many medications and treatments in the management of febrile illnesses (Jwara) and diseases of respiratory system (Pranavaha Srotsa) which are being practised since many years and are proven effective. Hence it is high time to evaluate its effect as a preventive measure in symptoms of respiratory system infection seen in COVID 19 patients. Ayurveda explains many medications andtreatments in the management of febrile illnesses (Jwara) and diseases ofrespiratory system (PranavahaSrotsa) which are being practised since many yearsand are proven effective. Hence it is high time to evaluate its effect as apreventive measure in symptoms of respiratory system infection seen in COVID 19patients. Rasayana is the Rejuvenation branch of Ayurvedic medicine. Rasayanatreatments were traditionally utilized after a period where the body waswarn-down or depleted. Rasayana therapies are also used to remedy old age,before the term ‘anti-ageing’, there was Rasayana. Many classical formulationsmentioned in Ayurvedic classic are excellent Rasayana medicines which can beused in treatment of various diseases including Jwara, Kasa, Kshaya.SamshamaniVati, KhadiradiVati, Dashmoola katutrayadi GhanVati are suchmedicines which can be useful in this condition. Nasya with AnuTaila inPratimarshaMatra (2 drops) is a remedy mentioned in Dinacharya that has shownbeneficial effects in many URTI conditions. Arsenic album 30 a homeopathicmedicine that is claimed to be beneficial in prevention from COVID 19infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 70.00 Year(s)（—）
- 性别
- All
入选标准
- •Subjects who are not suffering from active illness due to infecction at the time of inclusion.
排除标准
- •1.Subjects suffering from active illness due to infection at the time of inclusion.
- •2.Subjects suffering from uncontrolled DM, HTN etc.
- •Subjects who are known cases of immune-compromised or autoimmune condition such as HIV.
- •4.Pregnant and lactating women.
结局指标
主要结局
Episodes and severity of symptoms of respiratory tract infection (cold, sore throat, dry cough, breathlessness) in subjects who may get direct or indirect exposure to COVID 19 during lockdown in March and April 2020
时间窗: From Baseline till the end of 15 days
次要结局
- Incidence of COVID 19 infection in study population(From Baseline till the end of 15 days)
- Requirement of treatment for symptoms developed, if any, during study period(From Baseline till the end of 15 days)
- Analysis of adverse events, if any(From Baseline till the end of 15 days)